This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
BrainsWay® CMO, Dr. Aron Tendler, was interviewed by Corebrain Journal about Deep TMS and its usage an treatment for depression and other conditions.
[Deep] TMS provides some surprisingly fresh answers to previously “untreatable” psychiatric problems.This is how our interview with Dr Tendler started: he hit fresh interventions strategies hard – right out of the box – and continued with deep insights throughout our too-brief conversation. Note: He agreed to return now that we’ve had this opportunity for an introduction on this exceedingly interesting technology and treatment. dTMS does appear to provide significant answers for refractory responses on many levels – see this list of Indications that are currently under investigation – they’re more than just “interesting.”
Read more about the interview, and listen to the podcast here.